Key facts
- It has raised $1.6M; the latest was Accelerator/Incubator ($220K) in Mar 2026.
- Notable investors include Techstars, Innovation Works, AlphaLab, Surface Ventures, Westchester County Biosciences Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Concordare
- ·The full record, as it builds
Funding rounds
No funding rounds for Concordare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Concordare
Developer of clinical trial protocol digitization software designed to standardize and operationalize study documents. The company's platform offers artificial intelligence-based protocol conversion, automated generation of study tools, and system integration features, enabling clinical research sites and sponsors to manage trials from a single digital protocol source.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 3
- Website
- concordaretrials.com/
- Ownership
- Privately Held (backing)
Concordare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Concordare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Concordare in its N-PORT filings yet. We sweep new filings monthly.